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ABSTRACT 
BACKGROUND AND OBJECTIVE: Studies from the US and Canada observed changes in 
antihypertensive prescribing patterns in accordance with ALLHAT study findings immediately 
after the study’s publication, but little is known about the impact of ALLHAT in Italy.  The 
objective of this study was to examine antihypertensive prescribing patterns in Regione Emilia-
Romagna (RER), Italy, following the publication of the ALLHAT main results.  METHODS:  
We conducted a time series analysis using automated pharmacy data of approximately 4 million 
RER residents between January 1, 2000 and December 31, 2003.  We computed monthly relative 
percentages of prescriptions for all antihypertensive medications and separately for all new 
antihypertensives defined as no recorded antihypertensive use in the previous year.  A stepwise 
auto-regressive forecasting model based on data prior to ALLHAT publication was used to 
estimate predicted relative percentages for the 12 months following ALLHAT publication.  
Observed and predicted values were compared.  RESULTS AND DISCUSSION: Use of 
thiazide-type diuretics showed a general increasing  trend over the study period, but the 
difference between the observed and predicted values reached statistical significance only for 
new prescriptions in October 2003 (3.71% vs. 2.32%; p=0.0170).  The relative percentage of 
new angiotensin-converting enzyme inhibitor and angiotensin receptor blocker (ACE/ARB) 
prescriptions was higher than predicted for the months May to August 2003 (p<0.05), but no 
significant differences were observed for total ACE/ARB prescriptions.  Modest changes in 
patterns of prescribing of calcium channel blockers and α-blockers were observed.  
CONCLUSION: We found little evidence that the ALLHAT study had an impact on  
antihypertensive prescribing patterns in RER in the year following their publication. 
 
Key Words: hypertension, prescribing patterns, pharmacoepidemiology, , thiazide diuretic 
INTRODUCTION 
The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) 
is the largest randomized trial ever conducted to compare antihypertensive medications (1).  
Sponsored by the US National, Heart, Lung, and Blood Institute in conjunction with the US 
Department of Veterans’ Affairs, ALLHAT was designed to compare the efficacy of 4 types of 
antihypertensive medications – chlorthalidone (a thiazide-type diuretic), amlodipine (a calcium 
channel blocker [CCB]), lisinopril (an angiontensin-converting enzyme [ACE] inhibitor) and 
doxazosin (an α-adrenergic blocker) – for reduction of risk of coronary heart disease (CHD) or 
other cardiovascular events (1). 
 
The first patients were enrolled in February 1994, and follow-up was scheduled until March 
2002 (2).  In early 2000, the study investigators discontinued the α-adrenergic blocker arm 
because of an apparent increased risk of combined cardiovascular events among those receiving 
doxazosin as compared to those receiving chlorthalidone (2).  The main ALLHAT results, 
published in December 2002, showed that chlorthalidone was superior in preventing one or more 
major forms of cardiovascular disease and the investigators recommended that thiazide-type 
diuretics be the first line pharmacotherapy in the treatment of hypertension and, because many 
patients with hypertension require treatment with more than one antihypertensive, that thiazide-
type diuretics generally be included in any therapeutic regimen for the treatment of hypertension 
(2). 
 
The primary outcome of ALLHAT was a combined endpoint of fatal congestive heart failure and 
nonfatal myocardial infarction and secondary outcomes included all-cause mortality, stroke, 
combined congestive heart failure, and combined cardiovascular disease.  Specific results 
indicated that neither amlodipine (rate ratio [RR], 0.98; 95% confidence intervals [CI], 0.90-
1.07) nor lisinopril (RR, 0.99; 95% CI, 0.91-1.08) was superior to the referent, chlorthalidone, 
with respect to the primary endpoint.  A higher 6-year rate of heart failure was observed with 
amlodipine as compared to chlorthalidone (RR, 1.38; 95% CI, 1.25-1.52).  As compared to 
chlorthalidone, treatment with lisinopril resulted in higher 6-year rates of combined 
cardiovascular disease (RR, 1.10; 95% CI, 1.05-1.16), stroke (RR, 1.15; 95% CI 1.02-1.30), and 
heart failure (RR, 1.19; 95% CI 1.07-1.31). 
 
Despite limitations (3), the ALLHAT trial has had profound implications by shaping and 
bolstering clinical practice guidelines (4,5).  Several studies in the US and Canada even suggest 
that the ALLHAT results have had a significant impact on clinical practice since considerable 
increases in use of thiazide-type diuretics immediately following ALLHAT publication have 
been observed in these countries (6,7). 
 
Although results from North America are promising, Fretheim and Oxman have documented 
significant variations in antihypertensive prescribing between countries in general (8).  To date, 
little is known about trends in antihypertensive prescribing patterns in Italy following the 
ALLHAT publication.  Thus, the objective of this study was to assess the impact the ALLHAT 
publication on antihypertensive prescribing patterns in Regione Emilia-Romagna (RER), Italy. 
 
METHODS 
Data Source and Study Population 
We used outpatient prescription drug data from the RER administrative healthcare database, 
which has been described elsewhere (9,10).  In brief, this automated database comprises 
healthcare claims for all of the approximately 4 million RER residents.  We identified all 
recorded prescriptions for antihypertensive medications dispensed in RER between January 1, 
2000 and December 31, 2003.  Each antihypertensive medication was categorized into one of the 
following six classes: thiazide-type diuretics, ACE-inhibitors or angiotensin receptor blockers 
(ARBs), CCBs, beta-blockers, α-adrenergic blockers (α-blockers), and other antihypertensive 
diuretics.  Antihypertensive combination products (e.g. valsartan and hydrochlorothiazide) were 
excluded.  New antihypertensive prescriptions were defined as prescriptions for those individuals 
with no prescription records for any hypertensive medications in the previous 365 days.   
 
Analysis 
The number of all antihypertensive prescriptions and new antihypertensive prescriptions for each 
study month was determined.  The relative percentage of each antihypertensive class as a 
proportion of all antihypertensives or all new antihypertensives prescribed was computed for 
each study month.  Using the data from the period preceding the ALLHAT publication (January 
2000 to December 2002), we conducted time series analyses using stepwise autoregressive 
forecasting models (7).  In doing so, we estimated the predicted percentages and corresponding 
95% CI for each antihypertensive class for the 12 months following the ALLHAT publication 
(January 2003-December 2003) for both all antihypertensive prescriptions and new 
antihypertensive prescriptions.  We compared the observed percentages of prescriptions for each 
drug class to the predicted values using a value of α=0.05 for all comparisons.  Analyses were 
conducted using SAS version 8.1 (SAS Institute, Inc., Cary, NC)  
 RESULTS 
For the entire study period of 2000-2003, 46,967,917 antihypertensive medications were 
dispensed in RER.  An increasing trend in total antihypertensive prescriptions was observed over 
the study period (Figure 1).  The most commonly prescribed classes were ACEs/ARBs, which 
showed an overall increasing trend throughout the study period, and CCBs, which showed an 
overall decreasing trend throughout the study period (Figure 2).  Of all antihypertensives 
prescribed, 702,219 were identified as new prescriptions between 2001 and 2003.  Thiazide-type 
diuretics made up relatively small proportions of all and new antihypertensive prescriptions 
during the study period (Figure 2 and 3).  
  
All Antihypertensive Prescriptions 
No differences in overall prescribing patterns were observed for thiazide-type diuretics or 
ACEs/ARBs when comparing observed versus predicted relative percentages during the 12 
months following ALLHAT publication (Figure 2).  Overall use of CCBs and beta-blockers 
exhibited lower than predicted relative percentages for several months in 2003.  Use of α-
blockers was slightly higher than predicted during August 2003 to December 2003.  Observed 
relative percentages of other diuretics was slightly higher than predicted for the months 
September to December of 2003. 
 
New Antihypertensive Prescriptions 
Throughout 2003, the observed relative percentage of thiazide-type diuretics was similar to that 
predicted by the time series model (Figure 3).  New use of ACEs/ARBs was higher than 
predicted for the months May to August 2003.  Relative proportions of new use of CCBs were 
lower than those predicted by the time series model in every month except June 2003.  New use 
of beta-blockers was generally slightly higher than.  No differences in new prescription patterns 
were observed for other antihypertensive diuretics. 
 
DISCUSSION 
We found that the ALLHAT findings had little immediate impact on the prescribing of 
antihypertensives in RER in the year following the publication of the study’s main results.  Most 
importantly, little change in prescribing of thiazide-type diuretics was observed following the 
ALLHAT publication, despite the main ALLHAT finding of superiority of chlorthalidone over 
other types of antihypertensives for the prevention of cardiovascular outcomes.  We did observe 
modest changes in the prescribing of other antihypertensive medications in this time period.  
Because this study was conducted in only one region, caution should be used when extrapolating 
the results to the rest of Italy.  However, RER is a large region and we believe that prescribing 
patterns in RER likely reflect general prescribing attitudes throughout the country.  
 
The lack of a significant change in prescribing patterns in Italy is in stark contrast to findings in 
some other countries.  Following ALLHAT’s publication, Austin and colleagues found sharp 
changes in prescribing patterns of antihypertensive medications in Ontario, Canada (6).  
Consistent with the ALLHAT findings, these investigators observed a significant increase in new 
users of thiazide-type diuretics immediate following the ALLHAT publication and a significant 
decrease in new users of ACE-inhibitors and ARBs.  Similarly, using US-based prescription drug 
data, Xie and colleagues found a significant increase in use of thiazide-type diuretics 
immediately following ALLHAT publication (7).  Several other studies have corroborated these 
findings in these countries, at least in the short-term (11-14).  However, our study suggests that, 
unlike in North America, ALLHAT has had little or no impact on antihypertensive prescribing 
trends in Italy.  Similarly, Kabir and colleagues observed no difference in prescribing of thiazide-
type diuretics in Ireland (15).   
 
Explanations for this apparent dichotomy in the impact of ALLHAT results on antihypertensive 
prescribing in North American versus European countries can be postulated.  Fretheim and 
Oxman suggest that international variation in antihypertensive prescribing may be explained 
largely by differences in drug promotion practices (8).  Furthermore, many potential barriers to 
adoption of clinical evidence and clinical practice guidelines may exist, including lack of 
awareness, lack of agreement, inertia of previous practice, as well as a number of external 
barriers (16).  In addition, in Italy, drugs deemed clinically important, such as antihypertensives, 
are available to patients virtually free of charge.  Thus, financial incentives both for patients and 
physicians to manage hypertension with old, low-cost diuretics, as opposed to newer and often 
more expensive antihypertensives, are lacking and may contribute to inertia in clinical evidence 
adoption.  Causes of the reluctance in changing of prescribing habits and patterns are likely 
multifactorial and complex.  Nevertheless, the extent to which specific barriers to adoption of 
evidence-based medication prescribing affect some countries more than others is not known and 
warrants future research.   
 
Arguments that, because ALLHAT was conducted in North America and published in an 
English-language journal, the results are not directly applicable to non-English speaking 
physicians in Italy, are feeble, at best.  Large clinical trials, such as ALLHAT, generally yield 
results with biological implications applicable to many populations since biological mechanisms 
are ubiquitous regardless of the country in which one lives or the language that one speaks.  
Clinical evidence must transcend geographical boundaries and its adoption must not be impeded 
by language barriers. 
 
Furthermore, arguments that, because of differences in population characteristics and baseline 
prescribing patterns, the new clinical evidence produced by the ALLHAT study should not have 
an impact on antihypertensive prescribing patterns in RER rest on the notion that prescribing 
practices are, or are close to, optimal, such that the development and implementation of new 
clinical evidence would have only marginal effects on current prescribing trends.  However, 
antihypertensive prescribing is suboptimal in RER given the relatively low rates of prescribing of 
thiazide-type drugs found in this study and also when comparing thiazide-type prescribing rates 
in this study to the findings of Xie et al in the US (7).   
 
Indeed, Poluzzi and colleagues found that prior to ALLHAT publication, choice of initial drug 
treatment of hypertension among residents of RER did not accord with any major clinical 
guidelines (17).  We have also previously found evidence of potentially suboptimal drug 
prescribing practices in RER in other contexts (18-20).  Strategies to promote more appropriate 
medication prescribing and use in accordance with medical evidence and clinical guidelines are 
needed in Italy.   
 
Academic detailing programs can be effective in reducing suboptimal drug use (21,22).  Changes 
in reimbursement criteria to reflect evidence-based guidelines may also help improve prescribing 
patterns and promote evidence-based care (23).  Design of incentive-based programs should 
consider not only the prospective gain in health outcomes, but also the associated cost savings.  
Fischer and Avorn found that adherence to evidence-based prescribing guidelines for 
hypertension alone could result in enormous savings to health systems (24). 
 
The results of this study should be interpreted with the following limitations in mind.  First, this 
study utilized time series analysis which is useful as a quasi-experimental design to evaluate the 
influence of policies and other interventions on various measures of health resource utilization 
(25).  Such methods have been used widely in the study of outcomes associated with changes in 
and implementation of laws, programs, clinical guidelines, and health insurance and cost sharing 
policies in various countries (6,7,13,15,26-28).  Nevertheless, causal inference from time series 
analysis should proceed with caution (29), particularly since drug prescribing patterns may be 
influenced by many factors independent of a particular intervention.  For example, educational 
programs aimed at improving antihypertensive prescribing, changes in guidelines for the 
treatment of hypertension, and myriad policy changes could all affect prescribing patterns during 
the period of interest.  However, to the best of our knowledge, no major changes that could have 
significantly affected antihypertensive medication prescribing and use occurred in RER during 
the study period.  Examination of the study data further supports this notion since no observable 
major slope or level changes occurred in prescribing trends for any class of antihypertensive 
medications during the study period. 
 
This study was designed to examine only the immediate impact on antihypertensive prescribing 
patterns in the year following ALLHAT publication and provides little information about longer-
term changes in prescribing patterns beyond one year.  Indeed, evidence of considerable lag 
times in physician adoption of evidence-based guidelines and research findings have been 
observed in certain contexts (30).  However, several studies have demonstrated that physicians in 
some countries rapidly changed prescribing behaviors immediately after ALLHAT publication 
and that these changes were observable within the first year or less following publication, 
suggesting that a one-year window is sufficient to detect immediate changes in prescribing 
patterns (6,7,11-13).   
 
Another limitation is that many of the antihypertensive medications included in this study are 
used frequently for other indications.  Because of the nature of the prescription data, we were 
unable to link individual prescription records to their indications for use.  Thus, we included all 
antihypertensive medications (except for combination products) which inevitably included 
prescriptions intended for uses other than hypertension.  It is possible that this may have slightly 
diluted a true effect that the ALLHAT results may have had on prescribing patterns.  However, 
other studies which were subject to this same limitation still observed an impact of ALLHAT on 
prescribing patterns despite any dilution of the effect (6,7).  Thus, any dilution of the data in our 
study is not likely to have substantially affected our results.  Finally, no adjustments for multiple 
testing were made in this study so results of statistical comparisons should be interpreted with 
care.   
 
CONCLUSION 
We found little evidence that the ALLHAT study had an impact on antihypertensive prescribing 
patterns in RER in the year following their publication.  Use of thiazide-type diuretics was 
modestly increased after ALLHAT publication, but reached statistical significance for only one 
out of the 12 months of follow-up.  A better understanding of unresponsiveness to clinical 
evidence in Italy is needed, particularly as it pertains to changes in prescribing patterns.  
Programs that target evidence-based education or tie financial incentives to evidence-based 
prescribing practices may be warranted. 
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FIGURES 
 Figure 1. Trends in Use of Antihypertensive Medications in Regione Emilia-Romagna, 
Italy, 2000-2003 
 
Note: new prescriptions were identified as those for patients with no antihypertensive 
prescriptions in the previous 365 days.  Because data were available beginning in 2000, new 
prescriptions could only be identified beginning in 2001. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Relative Percentage of All Prescriptions for Antihypertensive Medications in 
Regione Emilia-Romagna, Italy, 2000-2003 
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Figure 3. Relative Percentage of Prescriptions for New Antihypertensive Medications in 
Regione Emilia-Romagna, Italy, 2000-2003. 
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